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Background
Dengue viruses are single-stranded pos-
itive-sense RNA viruses (genus Flavivirus,
family Flaviviridae) that are the etiological
agents of dengue fever (DF). More than 2
billion people live in dengue-endemic
areas [1–3], and dengue virus infections
account for an estimated 500,000 episodes
of severe disease each year [4]. A recent
review suggests that these may be under-
estimates [5]. Despite the fact that the
virus has been expanding in geographic
range over the past four decades [6–12],
there are still no licensed drugs or vaccines
and no consistently effective vector inter-
ventions to combat dengue. DF is caused
by four antigenically distinct viral sero-
types. Each type gives rise to both life-long
serotype-specific immunity and short-term
cross-protective immunity against the oth-
er serotypes thought to last between 2 and
9 months [13]. The spectrum of disease
ranges from asymptomatic infection to life
threatening dengue hemorrhagic fever
(DHF) and dengue shock syndrome
(DSS). The most distinctive feature of
dengue’s clinical/epidemiological profile
is the increased risk of severe disease
following infection by a heterologous
dengue serotype in an immunologically
primed individual. During this secondary
infection, a complex interaction is trig-
gered between the host’s immune system
and the infecting virus. In this setting,
elevated risk of severe dengue has been
attributed to the circulation of sub-neu-
tralizing concentrations of heterologous
anti-dengue virus antibody creating an
effect known as antibody-dependent en-
hancement (ADE) of infection and greater
viral burden in vivo [2,14–16]. In turn,
this leads to a host immune response that
is suggested to precipitate increased capil-
lary permeability, cardiovascular shock,
and hemorrhage characteristic of clinically
severe dengue. Viral and other host factors
may also contribute to pathogenicity. To
accurately assess the effects of dengue
vaccine candidates on individuals and
populations, these pathophysiological
mechanisms of severe dengue must be
understood.
The most advanced dengue vaccine
candidate—a live-attenuated, tetravalent,
chimeric yellow fever dengue vaccine—
commenced Phase II and Phase IIB
clinical trials in 2009, and Phase III trials
in December of 2010 [17–21]. Preliminary
results have demonstrated significant im-
munogenicity in all age groups after three
vaccine doses over a 12-month period.
Immunogenicity increased steadily with
each dose and was higher in individuals
with previous flavivirus immunity [21]. A
tetravalent dengue vaccine (TDV) candi-
date is currently the preferred formulation
of a dengue vaccine, as it should prevent
infection by all serotypes, thereby elimi-
nating the potential risk of severe infec-
tions associated with pre-existing immuni-
ty [22].
In line with the theory behind ADE,
subneutralizing antibody concentra-
tions—theoretically occurring when im-
munity is waning or between vaccine
doses—represent a potential risk of severe
dengue to patients infected with wild-type
virus during this critical period. This
individual-level risk can be evaluated
with sufficient follow-up, but popula-
tion-level effects cannot be analyzed in
the context of a vaccine trial. Population-
level immunity may change the propor-
tion of infections that occur in individuals
with partial immunity, and these infec-
tions may be associated with higher
viraemia and thus possibly higher trans-
mission, generating a potential indirect
detrimental effect of vaccination [23].
Although there is no evidence that
vaccine-derived immunity could lead to
increased severity or transmissibility upon
infection, given the immunopathogenesis
of dengue, this possibility should be
planned for.
Population-level effects, whether related
to ADE or not, can be analyzed with
mathematical models. Since it is not
feasible to enroll and randomize popula-
tions to dengue vaccine or placebo,
mathematical models may provide the
only environment where multiple types of
population-wide dengue strategies can be
evaluated. Models allow for assessment of
multiple intervention and evaluation strat-
egies. They can be used to understand the
specific population-level mechanisms by
which vaccines reduce incidence and can
aid in the design of evaluation studies. The
World Health Organization (WHO) has
recommended that mathematical models
be used to assess and inform various
methods of new vaccine introductions
[24,25].
To date, most models of dengue trans-
mission have been limited in scope and
focused on specific questions in transmis-
sion dynamics. However, many aspects of
the dynamics of dengue transmission are
still not fully understood. In order for
models to be accurate, realistic, and useful,
there is an urgent need for improved
understanding of dengue virology and
immunology, as well as the entomological,
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social, and environmental factors that
modulate dengue transmission. As these
facets of dengue biology are further
investigated, we will gain confidence that
future mathematical models may come
close to an accurate representation of true
dengue epidemics.
Mathematical Modeling
A mathematical model is a set of
equations or rules describing how a
certain process unfolds in time. Manipu-
lating these rules allows one to experi-
ment with components of the model to
explore their effects on the modeled
process as a whole, and it allows one to
compare predicted model outcomes with
observed data. Mathematical models of
disease transmission have three main
purposes: understanding the fundamental
driving forces of disease ecology and
epidemiology, measuring epidemiological
parameters that cannot be directly mea-
sured with field or laboratory data, and
making predictions of future disease
incidence under specified conditions. Re-
cent applied dengue modeling examples
include models to explore and validate
the effects of weather on the mosquito life
cycle [26], to estimate serotype-specific
forces of infection [27], to determine the
degree to which ADE enhances viral
fitness [28], to test if ADE alone is
sufficient to generate the oscillating sero-
type patterns seen in dengue [29,30], to
determine the impact that long-term
trends in dengue transmission rates may
have on DHF incidence [31], to deter-
mine if long-term demographic trends are
responsible for a shift in the age structure
of dengue cases [32], and to investigate
whether tertiary or quaternary dengue
infections are compatible with the known
epidemiology of dengue [33]. Although
none of these models included vaccina-
tion, they provide the necessary modeling
platform in which the impacts of alterna-
tive dengue control strategies, and vacci-
nation in particular, can be evaluated.
Some common dengue model structures
are shown in Figure 1.
Dengue modeling has been useful in
helping us understand the virus’ dynamics
and in generating some new hypotheses
about why the dynamics exhibit certain
irregularities, both short-term and long-
term. Nevertheless, when compared to
diseases such as influenza or malaria, the
dengue modeling literature is sparse and
focused on a small number of topics, often
serotype oscillations or antibody-depen-
dent enhancement. Given the importance
of mosquito populations to dengue trans-
mission, we have a relatively poor under-
standing of their population dynamics. In
addition, dengue models are rarely ana-
lyzed with a public health goal in mind,
and very little modeling has been done to
evaluate dengue interventions.
In developing an appropriate mathe-
matical model (or set of models) for
dengue vaccination, the main challenge
lies in resolving the complexity of interac-
tions among host immune status, demog-
raphy, vector populations, and environ-
mental factors. A current focus of much
modeling work is the strong interaction
between dengue immunology and epide-
miology. Through conferral of immunity,
dengue epidemics generate population-
wide immune profiles that subsequently
determine the severity, speed, and magni-
tude of dengue’s second pass through that
same population. Typically, as a dengue
epidemic progresses, surveillance focuses
on case numbers and severity without
recording changes in immune status; this
deprives us of essential data necessary for
understanding the immuno-epidemiology
of dengue. One of the greatest challenges
for epidemiologists and mathematical
modelers alike may be determining study
designs that can collect data on host
immune status as efficiently and complete-
ly as possible; such data sets may allow us
to describe the dynamics of population-
wide immunity and its effects on future
disease incidence.
Because we do not yet have a well-tested
general model of dengue immuno-epide-
miology, we cannot predict accurately
how a TDV would alter future dengue
dynamics. Mathematical modeling re-
search must thus start by identifying
realistic expectations for a TDV cam-
paign, given a varied set of scenarios for
vaccine introduction in a population.
These analyses may need to evaluate if
TDV rollout will have a greater impact on
case numbers or severity, and if vaccina-
tion-induced shifts in the age burden have
positive or negative impacts on overall
disease severity.
The next challenge will be to create a
set of public health objectives that will
Figure 1. Example structures of dengue models. The disease state space of five alternative
dengue model structures incorporating immune enhancement and short-term cross protection
are shown. The disease states are: S susceptible, E exposed but not yet infectious, Ii infectious with
serotype i, Iij infectious with serotype j having had serotype i, Ri recovered from and immune to
serotype i, Zij recovered from and immune to serotypes i and j and hence immune to all
serotypes, C temporarily cross-protected from all serotypes due to recent exposure. Model (a):
individuals immune to one serotype are more likely to experience a severe infection (denoted by
red box). Model (b): similar to model a with the addition of a pre-infectious exposed class E. Model
(c): includes a short-term cross-protection class C in which recently recovered individuals are
protected from infection for a certain amount of time. Model (d): model with short-term cross-
protection and increased infectiousness of class Iij indicated by red arrows showing an increase in
the rates of acquisition of primary and secondary infection due to this effect. Model (e): increased
transmissibility among secondary infections Iij to a mosquito species. Note that in this
formulation, mosquitoes that have obtained infection from a secondary human infection are
not more likely to transmit to humans. Subscripts h and m denote human and mosquito,
respectively.
doi:10.1371/journal.pntd.0001450.g001
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define the success of a dengue vaccination
campaign. Reduced case numbers, fewer
severe cases, and fewer deaths are all
potential marks of success, but these three
indicators may not correlate with one
another, either in the population as a
whole or across age classes. For example,
dengue in the elderly can be complicated
by comorbidities that increase the risk of
severe outcomes [34,35], and severity and
mortality rates can vary among age classes
[36]. Focused vaccination of children may
not reduce mortality rates in adults unless
herd immunity is achieved, but the level of
coverage needed to reach the threshold of
herd immunity has not yet been estab-
lished. Balancing these objectives may
prove difficult, as a vaccination campaign
could potentially prevent many infections
today while creating the conditions for
more infections in the future. Dengue
modeling may benefit from previous
mathematical modeling analyses of popu-
lation-level public health benefits in ma-
laria, influenza, and nosocomial infections
[37–39].
Because the interactions among key
determinants of dengue transmission, such
as environmental factors and vector biol-
ogy, are not well understood, exploring the
role of these determinants through mod-
eling will require significant effort. There
are still gaps in our understanding of short-
term cross protective immunity [13],
original antigenic sin [40–42], long-term
serotype-specific immunity [13,43,44],
ADE, the mode of action of the vaccine,
the association of infecting serotype se-
quence on disease severity [44–47], vari-
ation in mosquito biting patterns [48–51],
host variation in susceptibility and trans-
mission [30,52,53], population and vector
mobility [54,55], and virus dynamics
between dengue seasons [56]. All of these
factors should have an important effect on
the critical vaccination fraction—or, more
precisely, the age-stratified critical vacci-
nation fraction needed to interrupt dengue
transmission—as well as the optimal
design of a vaccination catch-up campaign
after the vaccine is introduced.
Dengue Vaccine Modeling
Group
To address these uncertainties and to
accelerate the development of mathemat-
ical models that can evaluate dengue
vaccination strategies, WHO and the
Vaccine Modeling Initiative (VMI) con-
vened a group of dengue epidemiologists,
clinicians, immunologists, public health
officials, vaccine developers, entomolo-
gists, and mathematical modelers to
discuss possibilities for assessing the pop-
ulation-wide impact of a tetravalent
dengue vaccine. This was the first such
meeting, which was hosted by WHO in
late 2010. Its purpose was to establish (1)
a forum for an inter-disciplinary working
group to discuss the development of
optimal dengue vaccination strategies,
and (2) future meetings with more experts
and stakeholders in dengue vaccination.
The WHO-VMI Dengue Vaccine Mod-
eling Group’s first phase of collaboration
has begun by linking modelers with
epidemiologists, clinicians, immunolo-
gists, and vaccine developers for the
purpose of conducting preliminary mod-
eling analyses on the risks and benefits of
dengue vaccination.
The initial questions identified by the
group as critical in assessing a dengue
vaccine are listed in Box 1. Future
meetings will need to include more experts
on virology, vector control, demographics,
environmental change and urbanization,
and economic and social aspects of dengue
burden. A second meeting is being
planned for 2012, the goals of which will
be to (1) evaluate progress of current
modeling and identify critical tests to
validate models, (2) identify the areas of
greatest uncertainty in dengue modeling,
(3) identify key data sets, reviews, and/or
meta-analyses that can aid the develop-
ment of models, and (4) broaden the
community of natural scientists, social
scientists, and policy makers involved in
research on dengue vaccination.
Parameterizing Models and
Data Sharing
The utility of models to assess vaccine
candidates depends on the models’ ability
to represent transmission dynamics accu-
rately. Measuring or estimating model
parameters is therefore a critical step in
constructing an accurate dengue model.
Some parameters can be measured direct-
ly from epidemiological or laboratory data
(duration of viraemia, mean age of first
infection), while in other cases models may
be used to statistically infer the impacts of
certain features of transmission dynamics
that cannot be measured directly (duration
of cross-protective immunity [57], effect of
disease severity on transmissibility). In
both cases, it is critical that modelers work
closely with dengue virologists and epide-
miologists who understand the lab/epide-
miological data and the parameter mea-
surements. These data will be critical for
the iterative process of model design and
validation.
Many of the individual-level parameters
concerning immunity and disease severity
are ideally measured in prospective cohort
studies with long-term follow up. Table 1
lists the known prospective cohort studies
that contain valuable individual-level data
on immune responses, differences between
primary/secondary infections, asymp-
tom?tlsb=.015w?>atic infections, disease
severity, and age burden. Equally valuable
data can be obtained from natural epi-
demics in populations where dengue has
been absent for a long time [44,58–60].
Analyzing these data with mathematical
models will be helpful for determining
many of the individual-level parameters
that are necessary for evaluating popula-
Box 1. Urgent Questions for Dengue Vaccination Roll-Out
1. Are there vaccine product profiles that could lead to increased transmission
from secondary infections?
2. What changes in age distribution of primary and secondary infection are
expected after vaccine introduction and mass immunization?
3. Given the demographics and force of infection in any particular setting, what is
the optimal age of vaccination and/or the age-stratified critical vaccination
fraction?
4. If vaccine efficacy depends on pre-existing immunity, what is the optimal age of
vaccination and/or the age-stratified critical vaccination fraction?
5. Should a vaccination strategy change given geographical variation in
transmission?
6. How should catch-up campaigns be implemented?
7. What immune escape or other viral evolutionary responses can be expected?
8. How should the immune system be represented in models?
9. How should individual risk profiles (i.e., the characteristics of an individual,
including past infections and vaccination status, that affect the individual’s risk
for severe dengue) be defined and modeled?
10. How should population-level vaccine effects be monitored?
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tion-wide dengue vaccination. As different
stages of clinical trials are completed in the
next several years, their results will also be
critical in improving the accuracy and
validity of mathematical models.
For all those involved—whether in
epidemiology, in clinical or laboratory
settings, or as modelers—it is critical that
complete data sets and the analysis of that
data be shared so that all the partners can
come to a common understanding of the
interpretation of the data. The recent
meeting in 2010 sought to catalyze this
effort by taking advantage of the partici-
pants’ varied skills and experiences and by
bringing together those scientists special-
izing in theory/modeling with those that
have a detailed understanding of the data.
Sharing and analyzing data from ongoing
and past studies will be critical for building
robust mathematical models of dengue.
The first small step in this partnership
will be the joint design and analysis of
mathematical models rooted in the most
recent epidemiological and laboratory
data, with each collaboration including
modelers and non-modelers.
Future Challenges
In addition to sharing data sets and
analyses and interpreting results, we must
recognize that dengue vaccination plan-
ning will probably happen alongside
vector control, social outreach and educa-
tional campaigns, multiple types of sur-
veillance, expansion of local capacity to
diagnose and manage dengue, and per-
haps novel entomological approaches of
reducing transmission by altering mosqui-
to ecology or genetics [61,62]. This
broader picture of dengue control may
not be easy to model mathematically, but
some of these aspects will need to be
evaluated in terms of their added popula-
tion-level benefits to dengue vaccination.
Currently, very little is known about the
effectiveness of modeling social dynamics
or modeling epidemics and response/
intervention policies in the context of
imperfect surveillance.
The mathematical models developed
through the joint effort of the modeling
community and dengue community will
give us prediction and evaluation tools that
can be used to determine optimal vacci-
nation strategies for each endemic coun-
try. Recommendations will be discussed
with national public health authorities and
adapted to the requirements and realities
of the host countries. When an implemen-
tation method is chosen for rolling out
dengue vaccines, appropriate and timely
surveillance activities should be planned so
that the effectiveness of the vaccination
strategy can be tested and adjusted in real
time. The implemented strategy will
almost certainly not be the one determined
to be optimal by a mathematical model,
Table 1. Prospective Dengue Cohort Studies.
Location Years Ages Follow-Up
Population
with Follow-Up Notes Reference




Koh Samui, Thailand 1966–1967 2–12 years 1 year 336 [64]
Yangon, Myanmar 1984–1988 2–6 years 1 year 3,579 Five separate cohorts
started each year. Includes
hospitalization data.
[47]
Bangkok, Thailand 1980–1981 4–16 years 6 months 1,757 [65]
Rayong, Thailand 1980–1981 4–14 years 1 year 1,056 [66]
Iquitos, Peru 1993–1996 7–20 years 2.5 years 129 No DHF/DSS found
in secondary cases.
[67]
Bangkok+Khamphaeng Phet, Thailand 1994–1996 6 months –
14 years
1 year 168 48 had follow-up
past 180 days.
[68,69]
Yogyakarta, Indonesia 1995–1996 4–9 years 1 year 1,837 [45]




Bandung, West Java, Indonesia 2000–2002 18–66 years 2 years 2,536 [73]









Managua, Nicaragua 2001–2003 4–16 years 1–2 years 999 [75]
An Giang, Vietnam 2004–2007 2–15 years 3 years .3,000 Additional children
recruited every year.
1,594 children had
3 years of follow-up.
[76]
Managua, Nicaragua 2004–ongoing 2–9 years 4 years 3,721 Includes entomological
indices.
[77,78]
Ho Chi Minh City, Vietnam 2006–2007 Newborns enrolled 1 year 1,244 infants [79]
Ratchaburi, Thailand 2006–2010 3–15 years 4 years ,3,000 Study ended. Unpublished
Colombo, Sri Lanka 2008–2010 ,12 years 2 years 800 Study ended. Unpublished
Ho Chi Minh City, Vietnam 2009–ongoing Newborns 1 year ,3,000 infants Unpublished
doi:10.1371/journal.pntd.0001450.t001
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but one that combines relevant aspects of
feasibility, cost-effectiveness, political ac-
ceptability, and public health benefits. We
must recognize that mathematical models
are at best fallible as prediction tools and
that the implementation process itself will
reveal new trends and facts that can be
used to improve future models and
recommendations.
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